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weight. The main objective is to conduct a pharmacoeconomic analysis to find out
the cost effectiveness of Diethylpropion with diet and exercise. (DEPDaE), com-
pared against Diet and Exercise (DaE) inMexico.METHODS:Thepoint of viewof the
study was the supplier of IMSS health services. The target population were men
andwomen over 18 years with BMI30 kg/m2. Outcomemeasures were the reduc-
tion of weight in kg and Quality Adjusted Life Years (QALYs). The direct costs in the
treatment of obesity were assessed, treatment of adverse events and complica-
tions (Type 2 Diabetes Mellitus and cardiovascular disease). We used a Dynamic,
Stochastic DiscreteModel (DSD) and a univariate and probabilistic sensitivity anal-
ysis was performed. All the quantities expresed in Mexican pesos (MXP) RESULTS:
DEPDaE presented a lower cost and improved the utility and effectiveness when
compared DaE. Incremental cost was $18,361MXP in males and $16,285MXP in
women. Incremental effectiveness and utility was 4.19 kg and 0.10 QALYs in men
and 3.77 kg and 0.08 QALYs in women. ICER pointed the absolute dominance for
DEPDaE. Estimated savings per 100 patients in the IMSS can be $1,697,027MXP if
complemented by a 100% change health habits using DEPDaE. CONCLUSIONS:
The combination of DEPDaE provides a cost effective improvement to the treat-
ment of patients with a risk profile for obesity.
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LEUKAEMIA (CLL)
Zinzani PL1, Connors JM2, Knight AD3, Crowe AM3, Jones R4, Tucker B5
1University of Bologna, Bologna, Italy, 2BCCA Centre for Lymphoid Cancer, Vancouver, BC,
Canada, 3Corvus Communications Limited, Buxted, UK, 4Genzyme Transplant and Oncology,
Oxford, UK, 5Genzyme Oncology, San Antonio, TX, USA
OBJECTIVES: Fludarabine (F) is amainstay treatment for CLL. Despite the availabil-
ity of an oral formulation with equivalent efficacy and improved patient accept-
ability, many centres use an IV generic formulation assuming it is cheaper. A
cost-minimisation analysis was undertaken on the two formulations. METHODS:
The model assessed oral vs IV F and combination with oral/IV cyclophosphamide
(FC). It included: European acquisition values defaulted to generic prices; body
surface area 1.75m2; mg/m2 dosages oral F 40, IV F 25, oral C 150, IV C 250; dosage
days/cycle F 5 / FC 3 for 6 cycles/patient. Published adverse events rates were
equivalent except for IV administration complications (8% default) and diarrhoea
(oral F 34.6% vs IV F 11.3% Grade 1/2 and 3.8% vs 0%  Grade 3/4)  2% managed
in hospital. Equipment and clinical resource costs were defaulted to published
rates and authors’ centres. A sensitivity analysis assessing minimum and maxi-
mum potential costs was applied. RESULTS: Acquisition costs per treatment
coursewere higher for oral vs IV (F - €5,334 vs €1,313 FC - €3,213.16 vs €894). However
IV costs increased with adverse events (oral vs IV complications mean €0 vs €40,
diarrhoea €1 vs €0) and hospital resource costs (oral vs IV F - €18 vs €4,200, FC- €18
vs €2,520). Direct oral vs IV treatment costs per patient were F - €5,353 vs €5,553
(range €5,334-€5,353 and €5,513-€5,577), FC - €3,232 vs €3,454 (range €3,214-€3,233
and €3,414-€3,478). Modelling oral adoption in 100 patients - 80% IV F / 20% IV FC, a
100% and 90% switch respectively resulted in €19,943 mean cost savings, releasing
funding and resources for improved care and patient throughput. CONCLUSIONS:
Oral fludarabine acquisition costs are higher than generic IV, but cost-minimisa-
tionmodelling demonstrated reduced direct costs with oral fludarabine, while also
being preferred by patients.
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OBJECTIVES: Recent randomized trials (RCT) have suggested erythropoiesis stim-
ulating agents (ESA) reduce mortality in critically ill trauma patients; however ESA
are costly. We sought to determine cost-effectiveness of ESA in this patient
population.METHODS: A decision analytic model was constructed to compare the
use of ESA to standard care in trauma patients admitted to an intensive care set-
ting. Base case costs and benefits at one year were estimated using mortality esti-
mates from available RCTs. One way and probabilistic sensitivity analyses were
conducted for comparison of the base case scenario with 10 and 25 year time
horizons inMarkovmodels.RESULTS: ESAusewas associatedwith a cost per QALY
gained of $74,500 to $81,748 compared with standard care at one year. One-way
sensitivity analyses indicated results were sensitive to changes in mortality risk,
risk of thrombosis, relative risk ofmortality, relative risk of thrombosis, and quality
of life estimates. Cost effectiveness acceptability curves generated from probabi-
listic sensitivity analysis indicated that the probability ESA would be considered
attractive ranged from 35% to 80% over the range of WTP of $60,000 to $120,000.
Consideration of longer time horizons reduced the cost per QALY gained to $9,338 
$5,957. CONCLUSIONS:While the cost per QALY gained with ESA use falls into the
range of currently accepted healthcare technologies funded in Canada, significant
uncertainty exits, particularly long-term survival benefit with ESA use. Further
research into the efficacy and safety of ESA use in critically ill trauma patients is
required prior to widespread use.
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OBJECTIVES: To examine cost-utility of different erythropoietins (epoetin alfa and
epoetin beta) in Russian anemic patients on dialysis.METHODS: Health survey of
patients in dialysis departments of 23 regions. About 1400 questionnaires were
distributed in May - June 2010. Health-related quality of life was assessed with
self-administrated validated version of Russian version of Euroqol-5D question-
naire. Inclusion criteria were age older than 18 years, terminal stage of chronic
renal failure and treatment with dialysis more then 4 months. All patients have
been divided on four subgroups depending on the name of received erythropoietin.
Direct cost contains of cost of erythropoietin, administration cost, cost of iron
supplemention was calculated. RESULTS: 1395 completed questionnaires were re-
ceived by September, 2010. Detailed analysis of antianemic therapy has shown that
85% patients received erytropoetins. There were four the most used drugs: Recor-
mon (epoetin beta) (42%), Eralfon (epoetin alfa) (18%), Epocrinum (epoetin alfa)
(16%), Eprex (epoetin alfa) (9%). Groups were not differ according to the level of
hemoglobin. Average HRQL, assessed with VAS, was not differ significantly be-
tween 4 groups: 0.62 for Eralfon, 0.59 for Recormon, 0.585 for Eprex, 0.56 for Epoc-
rinum. Per year cost of treatment with Eprex was 5 382 USD, with Eralfon – 4 463
USD, with Recormon – 4 204 USD, with Epocrinum – 1 652 USD. Lifelong costs of
treatment with Eprex was 50 017 USD, with Eralfon – 49 098 USD, with Recormon –
48 785 USD, with Epocrinum – 46 596 USD. The cost per QALY was 85 499 USD per
QALY for Eprex, 83 505 USD per QALY for Epocrinum, 82 547 USD per QALY for
Recormon and 75 596 USD per QALY for Eralfon. CONCLUSIONS: Present cost-
utility analyses revealed that in Russian anemic patients on dialysis the most
cost-effective strategy of antianemic therapy among 4 common erythropoietins
was Eralfon with 75 596 USD per QALY.
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OBJECTIVES: Inflammatory Bowel Disease (IBD) is an immune-mediated inflam-
matory disorder which includes Crohn’s disease and ulcerative colitis. The rela-
tionship betweenout-of-pocket (OOP) healthcare costswith productivity is notwell
known in IBD. This study explores the relationship of OOP healthcare costs on
productivity. METHODS: Participants self-identified with IBD and aged 18 com-
pleted an internet-based cross-sectional survey in 1Q2009. Self-reported produc-
tivity loss including absenteeism, presenteeism, overall work impairment and ac-
tivity impairment expressed as impairment percentages, were measured by the
Work Productivity andActivity Impairment questionnaire. Participantswere asked
about IBD-related and overall monthly OOP healthcare costs. Negative binomial
regression models were developed to adjust for age, gender, ethnicity, income,
education, and marital status. RESULTS: 534 participated, 67% were female, 55%
were employed, and 13% were on short- and long-term disability. More than half
(53%) reported annual household incomes between $50-100K, 40% were college
educated. Overall OOP costs were: $0-$50 for 52.6%, $51-$100 for 18.2%, $101-$200
for 15.5%, and  $200 for 13.7%. Among employed, rates of absenteeism, presen-
teeism, and overall work impairment were 9.97%, 16.3% and 20.0%, respectively.
43.2% reported impairment in daily activities. Significantly greater productivity
loss (presenteeism, b 2.79, p 0.0004) and overall work impairment (b 2.78, p
0.0006) were observed among patients with overall OOP costs $200, as compared
to those with OOP costs between $0-50 after adjusting for patient demographics.
CONCLUSIONS: Higher monthly OOP costs were associated with higher work im-
pairment and lower productivity. Shifting healthcare costs to employees maybe
associated with productivity loss. Further research is needed to determine longer-
term impact of OOP healthcare costs on work productivity.
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OBJECTIVES: Hyponatremia (HN) is the leading electrolyte abnormality among
hospitalized patients. In the absence of symptoms, HN is often overlooked as a
condition that warrants aggressive intervention. Though HN is common, little is
known regarding the influence of HN on patient outcomes and healthcare resource
utilization. This study assessed the impact of HN on inpatient total and intensive
care unit (ICU) cost, total and ICU length of stay (LOS), likelihood of ICU admission,
and 30-, 90-, and 180-day readmission. METHODS: Premier’s Perspective® data-
base was utilized to construct a stratified sample of hospital inpatients discharged
between January 1, 2007 and June 30, 2009. HN patients were identified using pri-
mary or secondary diagnosis of HN (n558,815) and were matched to a non-HN
control group (n558,815) using exact matching of age, gender, provider region,
and 3M™ APR-DRG assignment. Matching was further refined using propensity
scores based on additional patient and hospital characteristics and patient comor-
bidities. Cost was analyzed using a multivariate general linear regression model
with gammadistribution and log-link, LOSwith negative binomial distribution and
log-link, and ICU admission and hospital readmission with multivariate logistic
regression. RESULTS: In contrast to non-HN patients, patients with HN had signif-
icantly higher total inpatient cost (9.49%, CI8.99-10.00; p.0001), ICU cost (9.12%;
CI8.04-10.23; p.0001), total LOS (12.24%, CI11.85-12.64; p.0001), and ICU LOS
(11.06%, CI9.60-12.54; p.0001). HN patients were significantly more likely to be
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admitted to the ICU (OR1.027, CI1.016-1.037; p.0001), and readmitted at 30
(OR1.129, CI1.118-1.141; p.0001), 90 (OR1.185, CI1.175-1.196; p.0001), and
180 (OR1.163, CI 1.153-1.173; p.0001) days post discharge compared to
non-HN patients. CONCLUSIONS: HN represents a significant clinical, utiliza-
tion, and economic burden due to increased cost, LOS, ICU admissions and
hospital readmission.
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OBJECTIVES: To evaluate and compare changes in healthcare resource utilization
and costs associated with the initiation of pregabalin or gabapentin in pDPN pa-
tients in a real-world setting.METHODS: A retrospective cohort study utilizing the
MarketScan Commercial Claims and Encounters Database (2007-2009). Patients
with a new prescription for pregabalin or gabapentin in 2008 (date of the prescrip-
tion defined as index date) and 1 healthcare encounter with an ICD-9 code for
diabetic peripheral neuropathy (DPN; 250.6 or 357.2) within 30 days prior to the first
prescription for pregabalin or gabapentin were identified and propensity score
matched. Both cohorts were continuously enrolled for the 12month pre- and post-
index periods during which health care utilization and costs were assessed. Pre- to
post-index changes were compared between pregabalin and gabapentin using a
difference-in-difference (DID) approach. RESULTS: 910 pregabalin patients (48.6%
female;mean age 63.312.1 years) werematched to 910 gabapentin patients (48.8%
female; mean age 63.312.1 years); other demographic and clinical characteristics
were also comparable between cohorts,with the exception of US region. The pre- to
post-index DID in resource utilization did not differ between the two cohorts in-
cluding: number of office visits per patient (P0.66), number of ER visits (P0.78),
number of inpatient stays (P0.92), average inpatient length of stay per hospital-
ization (P0.79), number of total prescriptions filled (P0.37). The DID of total
healthcare costs per patient were non-significant with pre- to post-index increases
of $3,081 in pregabalin patients and $4,683 in gabapentin patients (P0.50).
CONCLUSIONS: Patients with pDPN initiating pregabalin or gabapentin experi-
enced comparable changes in healthcare resource utilization and costs. These re-
sults suggest overall cost neutrality between pregabalin and gabapentin.
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OBJECTIVES: To identify the factors associated with high healthcare expenditure
among obese individuals in the United States. METHODS: Analytical sample con-
sisted of obese adults 20 years or olderwith (BMI30). Total yearly expenditures for
obese adults were obtained from 2007 Medical Expenditure Panel Survey data.
Observations with total yearly healthcare expenditure greater than 90th percentile
were classified as high healthcare expenders and coded yes/no to be used as the
dependent variable. Independent factors selected according to the Anderson’s Be-
havioral Model were age, gender, race, MSA, region, education, poverty category,
source of payment, usual source of care, MSA, education, general health status,
mental health status andmortality risk status. ‘Surveylogistic’ regressionwas used
to determine the predictors of high expenditures. RESULTS: Descriptive analysis
show that adults with high healthcare expenditure were whites (74.23%), hadmid-
school education (60%), lived in MSA (79%), had usual care provider (95%), private
insurance (67%) and belonged to very high mortality risk group (46%). In adjusted
analysis, age (OR: 1.019 CI: 1.009-1.029), usual source of care (OR: 1.901 CI: 1.196-
3.020), private (OR: 3.609 CI: 1.992-6.539) and public insurance (OR: 3.251 CI: 1.781-
5.936), very high (OR: 3.342 CI: 2.327-4.798) and high (OR: 2.213 CI: 1.666-2.938)
mortality risk and general health status (OR: 2.493 CI: 2.148-2.893) were associated
with high healthcare expenditure. CONCLUSIONS: Several enabling and need fac-
tors seem to be associated with high healthcare expenditure. Both private and
public health insurance have a significant burden of healthcare expenditure asso-
ciated with obesity. Individuals with usual source of care are more likely to incur
high healthcare expenditure. Comorbidities have a significant impact on health-
care expenditure among obese individuals and highlight the need to deliver com-
prehensive disease state management. The findings from this study can have im-
portant implications in understanding increased utilization of health services
among obese adults in the United States.
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OBJECTIVES: Although both oxycodone CR and oxymorphone ER are approved for
twice daily dosing, it is unclear whether actual utilization is consistent with this.
The objective was to assess whether there exist differences in the utilization of
oxycodone CR and oxymorphone ER.METHODS:We used prescription claims data
from a commercially-insured population (i3 InVision Data Mart database), during
the period January 1, 2007 to March 31, 2010. A claim for at least one 30-day supply
of study drug one month prior to the observation period was necessary to avoid
capturing utilization associated with titration. Subsequently, all subjects had a
claim for at least a 90-day supply of the respective opioid analgesic. Patients’ claims
were excluded from this analysis if there was evidence of a switch from one to the
other study opioid during the 90-day observation period. Therewere no limitations
on the use of other opioids, during the baseline or observation periods. The final
cohort consisted of 6,567 oxycodoneCRpatients and 796 oxymorphone ERpatients.
In addition to univariate analysis, multivariate analyses were conducted using
generalized linear models (GLM) to adjust for the observed heterogeneity among
patients in the observational database. RESULTS: The unadjusted daily average
supply (DASUP)mean values for the highest strengths of oxycodone CR (80mg)was
3.9 compared to 2.9 for oxymorphone ER (40mg), 3.0 vs. 2.4 for all lower strengths,
and 3.1 vs. 2.5 for all strengths. (all p0.001). After adjusting for baseline differ-
ences, a risk-adjusted overall mean difference in DASUP remainedwith oxycodone
CR patients receiving, on average, 0.6 tablets more per day than those dispensed
oxymorphone ER (p0.001). The direction, magnitude and statistical signifi-
cance of these differences were essentially unchanged in sensitivity analyses.
CONCLUSIONS: In managing the pharmacy benefit, decision-makers may want to
consider the financial implications of these DASUP differences.
Systemic Disorders/Conditions – Patient-Reported Outcomes & Preference-Based
Studies
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OBJECTIVES:There is a rapidly growing overweight and obesity epidemic in theUS,
and a high demand for long-term safe and effective weight-loss agents. While 3
new antiobesity therapies underwent FDA review in 2010, little is known about the
utilization of available weight-loss drugs. The objective of this analysis is to de-
scribe the real-world prescription patterns, adherence, and persistence of weight-
loss pharmacotherapy in the United States. METHODS: A retrospective cohort
analysis was conducted using Medco’s integrated claims database to evaluate
adult patients initiating weight-loss pharmacotherapy between May 2007-October
2010. Eligibility criteria included new weight-loss drug prescription claims (no
weight-loss therapy prescriptions 6 months prior to index claim date) and contin-
uous eligibility for 6months pre- and 14months post-index claim date. Patients on
drugs with 1000 distinct patient counts were analyzed for adherence (annual
Medication Possession Ratio; MPR), persistency (allowing a 45 day gap), and con-
comitant therapy. RESULTS: Analyses included 91,160 patients receiving five
drugs: phentermine (N67434), sibutramine (N13438), orlistat (N8047), phendi-
metrazine (N4631), and, diethylpropion (N 4350). MeanSD age was 4412
years (96%, 18-64 y/o), 82% were female, 46% resided in the South, and 91% filled
prescriptions at retail only. Among obesity drug prescribers with known specialty,
71% were family/internal medicine practitioners. Patients received a mean of 33
concomitant chronic medications, with 38%, 31%, 22%, and 11% on antihyperten-
sive, antidepressant, dyslipidemia, or oral antidiabetic therapy, respectively. The
mean adherence ranged fromMPR0.20 (phendimetrazine) toMPR0.26 (phenter-
mine). Persistence at 3, 6, and 12 months ranged respectively from 26%-38% (low-
phendimetrazine, high-phentermine), 9%-16% (low-phendimetrazine, high-sibut-
ramine), and 3%-6% (low-phendimetrazine, high-sibutramine). CONCLUSIONS:
Weight-loss pharmacotherapies in the United States were prescribed by primary
care physicians to predominantly younger, female patients on concomitant ther-
apy for common obesity-related conditions. Adherence and persistence to therapy
is low, even over short-term exposure, although treatment duration may extend
beyond recommendations in some cases (e.g., phentermine).
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OBJECTIVES:Hemophilia A is a rare but serious bleeding disorder caused by a blood
clotting factor VIII (FVIII) deficiency. To examine the impact of hemophilia A and
replacement FVIII therapies from a humanistic and economic perspective, a tar-
geted literature review was conducted. METHODS: Searches were conducted in
MEDLINE® and the National Health Service Economic Evaluation Database, using
disease, patient-reported outcome and economic-related key words, limited to
English articles published from January 2000-January 2010 (inclusive). From 653
abstracts retrieved, 34 full-text articles were selected for detailed consideration.
RESULTS: Findings revealed increased mortality rates and decreased life expec-
tancy among people with hemophilia A, compared with the general population.
This is largely attributed to the transmission of blood-borne viruses (e.g. HIV and
Hepatitis-C) due to use of plasma-derived FVIII (pdFVIII) concentrates. Improve-
ments in viral attenuation processes plus donor screening practices for pdFVIII
products have reduced the risks of viral transmission, but risk fromnon-enveloped
viruses and other unknown pathogens still exists. Newly developed recombinant
FVIII therapies minimize these risks; however, such therapies are not currently
widely available globally. All available FVIII therapies use demanding regimens
requiring regular time-consuming injections,which can be detrimental to patients’
health-related quality of life and limit adherence. Non-adherence is associated
with diminished product efficacy, poorer health outcomes and increasing eco-
nomic expenditure. Treating hemophilia A is costly, primarily due to the high
acquisition cost of replacement FVIII products. However, indirect costs (e.g. patient
disability) also contribute to economic burden. Prophylactic treatment, while ini-
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